A Review of Driver Genetic Alterations in Thyroid Cancers
- PMID: 30697281
- PMCID: PMC6339486
A Review of Driver Genetic Alterations in Thyroid Cancers
Abstract
Thyroid cancer is a frequent endocrine-related malignancy with continuously increasing incidence, and recently the development in understanding its molecular pathogenesis is mainly through the explanation of the original role of several key signaling pathways and related molecular distributors. Central to these mechanisms are the genetic and epigenetic alterations in these pathways such as mutation and DNA rearrangements. However, it does not mean that all the somatic abnormalities in a cancer genome are involved in cancer development and just driver mutations are concerned in tumor initiation. By way of illustrations, MAPK pathway motivated by BRAF V600E and RAS and RET / PTC rearrangements are suggesting driver genetic alterations in follicular derived thyroid cancers considered in the current review.
Keywords: MAP kinase signaling system; Proto Oncogene Protein B raf; Proto-Oncogene Proteins p21(ras); Thyroid Cancer.
Conflict of interest statement
The authors declared no conflict of interest.
Figures




Similar articles
-
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.Cancer. 2010 Jun 15;116(12):2974-83. doi: 10.1002/cncr.25061. Cancer. 2010. PMID: 20564403
-
BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. J Chin Med Assoc. 2010. PMID: 20230995 Review.
-
[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Endocrinol Nutr. 2009. PMID: 19627734 Review. Spanish.
-
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22. J Clin Endocrinol Metab. 2012. PMID: 22442268
-
[Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].Mol Biol (Mosk). 2004 Jul-Aug;38(4):642-53. Mol Biol (Mosk). 2004. PMID: 15456136 Russian.
Cited by
-
Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review).Mol Clin Oncol. 2023 Nov 2;19(6):99. doi: 10.3892/mco.2023.2695. eCollection 2023 Dec. Mol Clin Oncol. 2023. PMID: 38022847 Free PMC article. Review.
-
Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review.Medicina (Kaunas). 2022 May 17;58(5):666. doi: 10.3390/medicina58050666. Medicina (Kaunas). 2022. PMID: 35630083 Free PMC article. Review.
-
Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.Medicina (Kaunas). 2021 Oct 19;57(10):1131. doi: 10.3390/medicina57101131. Medicina (Kaunas). 2021. PMID: 34684168 Free PMC article. Review.
-
Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.Cancers (Basel). 2020 Jul 29;12(8):2104. doi: 10.3390/cancers12082104. Cancers (Basel). 2020. PMID: 32751138 Free PMC article. Review.
-
Identification of KIT and BRAF mutations in thyroid tissue using next-generation sequencing in an Ecuadorian patient: A case report.Front Oncol. 2023 Jan 17;12:1101530. doi: 10.3389/fonc.2022.1101530. eCollection 2022. Front Oncol. 2023. PMID: 36733350 Free PMC article.
References
-
- Curado M-P, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents. Vol 4. Lyon: IARC Press, International Agency for Research on Cancer; 2007.
-
- Larijani B, Shirzad M, Mohagheghi M, Haghpanah V, Mosavi-Jarrahi A, Tavangar S, et al. Epidemiologic analysis of the Tehran cancer institute data system registry (TCIDSR) Asian Pac J Cancer Prev. 2004;5(1):36–9. - PubMed
-
- Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi A, Tavangar S, Malekzadeh R, et al. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80–5. - PubMed
-
- Larijani B, Mohagheghi MA, Bastanhagh MH, Mosavi-Jarrahi AR, Haghpanah V, Tavangar SM, et al. Primary thyroid malignancies in Tehran, Iran. Med Princ Pract. 2005;14(6):396–400. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous